Moderna, Inc. (MRNA) 今日盘中股价大跌6.37%，引起了市场的广泛关注。
消息面上，Leerink Partners将Moderna的目标价从21美元上调至24美元，但维持了“跑输大盘”的评级。这一目标价远低于当前股价，也明显低于分析师的一致目标价，反映出部分机构对公司近期大幅上涨后的谨慎态度。此前，公司因mRNA流感疫苗获得FDA顾问委员会推荐、德国产能扩张计划等多重利好，股价在短期内已累计大幅上涨，这些利好已被市场充分消化，导致短期获利回吐压力集中显现。
市场预计，FDA对该流感疫苗的最终审批决定将在8月初做出，在此之前，市场可能进入一个消息真空期，加剧了股价的波动和调整压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.